The Live Nagpur
  • Nagpur City
  • Nagpur Education
  • Nagpur Sports
  • Business
  • Featured
  • Crime
  • Entertainment & Lifestyle
  • Health & Wellness
  • Nation
  • Politics
  • Trending
  • Vidarbha
  • Obituary

The Live Nagpur

  • Home
  • City
  • Politics
  • Business
  • Education
  • Entertainment
  • Sports
  • Health
  • Crime
  • Forest
  • Featured
  • Vidarbha
Health & Wellness

COVID-19: Hetero and Cipla get India’s drug regulator nod for antiviral drugs Remdesivir

by TLN Team June 21, 2020
written by TLN Team June 21, 2020
COVID-19: Hetero and Cipla get  India’s drug regulator nod for antiviral drugs Remdesivir

Another good news for India who has been fighting with the deadly Coronavirus from the past 3 months as Hetero and Cipla have been given a nod by India’s drug regulator to manufacture and market antiviral drugs Remdesivir for “restricted emergency use” on hospitalised Covid-19 patients.

“The approval to Hetero and Cipla was given on Saturday,” news agency PTI quoted a source as saying.

With this written informed consent of each patient is required before the use of remdesivir and results of additional clinical trials, active post-marketing surveillance data, and reporting of serious adverse events have to be submitted.

The Union health ministry, in its ‘Clinical Management Protocols for COVID-19’, recommended the use of remdesivir on patients in the moderate stage of the disease that is, those on oxygen.

The drug has been included as an “investigational therapy” only for restricted emergency use purposes.

Gilead Sciences had applied to the Indian Drug Regulatory Agency, Central Drug Control Standard Organisation (CDCSO), for import and marketing of remdesivir on May 29. After due deliberations, permission under emergency use authorisation was granted by DCGI on June 1 in the interest of patient safety and obtaining further data.

Although Cipla and Hetero have not officially confirmed the news.

Recently Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19. The drug will be available as a prescription-based medication for Rs 103/tablet, with recommended dose being 1800 mg twice daily on day 1, followed by 800 mg twice daily up to day 14.

0 comment
FacebookTwitterLinkedin
TLN Team

previous post
Decriminalising Bouncing of Cheques will Increase Hardship: Dipen Agrawal, President-CAMIT
next post
CAIT sought support of chief ministers of all states for its boycott Chinese goods campaign

You may also like

‘Open heart surgery’ on 9-month-old baby;

June 6, 2023

Power outage at Daga Hospital for more than...

June 5, 2023

40 Medical Colleges lose recognition, 100 more under...

May 31, 2023

“I made a promise to my father…” Sachin...

May 31, 2023

NMC releases route map for bicycle rally on...

May 29, 2023

Son donates liver to save father’s life

May 27, 2023

Massive Turnout of 50,000 at ‘Yoga Mahotsav’ in...

May 27, 2023

AIIMS, Nagpur conducts an Awareness program on World...

May 25, 2023

Genomic Sequencing Laboratory at VRDL, AIIMS, Nagpur gets...

May 22, 2023

ENDOSCOPIC BRAIN SURGERY ON A 10 YEAR OLD...

May 18, 2023

Trending News

  • A woman asks if 40LPA salary is enough to survive in India, twitteratis give hilarious answers!

    June 8, 2023
  • With 29% rise, Maharashtra attracts highest FDI

    June 7, 2023
  • Cricket fever on! Will rain spoilsport Ind vs Aus mega clash?

    June 7, 2023
  • Apple launches the thinnest MacBook Air with 18-hour battery life.

    June 6, 2023
  • Coromandel express accident: Train derailment in Odisha leaves over 200 dead, 900 injured

    June 3, 2023

Important Links

  • Politics
  • Crime
  • Business
  • Education
  • Entertainment
  • Sports

Available on Playstore & Coming Soon on Appstore

Sign-Up Form

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

Footer Logo
  • Nagpur City
  • Nagpur Education
  • Nagpur Sports
  • Business
  • Featured
  • Crime
  • Entertainment & Lifestyle
  • Health & Wellness
  • Nation
  • Politics
  • Trending
  • Vidarbha
  • Obituary
  • Privacy Policy
  • Cookie Policy
  • Terms Of Use
  • Advertise with Us

© 2020 - The Live Nagpur . All Rights Reserved.